Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHARD: Phase 2 Platform Study of Resistance-Directed Therapies in Post-Osimertinib NSCLC
NCT03944772Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 9
01
Overview
A Phase 2 trial of osimertinib, savolitinib, gefitinib, necitumumab, durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jun 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03944772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944772.